Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s share price shot up 4.8% on Monday . The company traded as high as $0.24 and last traded at $0.22. 14,142 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,993,717 shares. The stock had previously closed at $0.21.

Several equities analysts recently weighed in on GNMX shares. ValuEngine lowered shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a report on Thursday, December 20th. JMP Securities lowered shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd.

The firm has a market cap of $14.83 million, a price-to-earnings ratio of -0.25 and a beta of 0.32.

A hedge fund recently bought a new stake in Aevi Genomic Medicine stock. Bridgeway Capital Management Inc. bought a new position in Aevi Genomic Medicine Inc (NASDAQ:GNMX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 223,500 shares of the biotechnology company’s stock, valued at approximately $275,000. Bridgeway Capital Management Inc. owned about 0.35% of Aevi Genomic Medicine as of its most recent filing with the Securities and Exchange Commission. 19.18% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Aevi Genomic Medicine (GNMX) Shares Up 4.8%” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Story: Do back-end load funds outperform no-load funds?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.